HARTE-HANKS INC (HHS) Fundamental Analysis & Valuation

NASDAQ:HHS • US4161962026

Current stock price

2.75 USD
-0.02 (-0.72%)
Last:

This HHS fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

3

1. HHS Profitability Analysis

1.1 Basic Checks

  • HHS had negative earnings in the past year.
  • In the past year HHS has reported a negative cash flow from operations.
  • In multiple years HHS reported negative net income over the last 5 years.
  • In multiple years HHS reported negative operating cash flow during the last 5 years.
HHS Yearly Net Income VS EBIT VS OCF VS FCFHHS Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 -50M -100M

1.2 Ratios

  • With a decent Return On Assets value of -0.88%, HHS is doing good in the industry, outperforming 67.03% of the companies in the same industry.
  • HHS has a Return On Equity of -3.95%. This is in the better half of the industry: HHS outperforms 62.64% of its industry peers.
  • HHS's Return On Invested Capital of 2.78% is in line compared to the rest of the industry. HHS outperforms 59.34% of its industry peers.
  • Measured over the past 3 years, the Average Return On Invested Capital for HHS is in line with the industry average of 7.76%.
  • The 3 year average ROIC (7.14%) for HHS is well above the current ROIC(2.78%). The reason for the recent decline needs to be investigated.
Industry RankSector Rank
ROA -0.88%
ROE -3.95%
ROIC 2.78%
ROA(3y)-10.64%
ROA(5y)1.85%
ROE(3y)-50.52%
ROE(5y)N/A
ROIC(3y)7.14%
ROIC(5y)10.79%
HHS Yearly ROA, ROE, ROICHHS Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 -1K -2K -3K -4K

1.3 Margins

  • The Operating Margin of HHS (1.36%) is comparable to the rest of the industry.
  • HHS's Operating Margin has declined in the last couple of years.
  • HHS's Gross Margin of 18.08% is on the low side compared to the rest of the industry. HHS is outperformed by 72.53% of its industry peers.
  • HHS's Gross Margin has improved in the last couple of years.
Industry RankSector Rank
OM 1.36%
PM (TTM) N/A
GM 18.08%
OM growth 3Y-42.96%
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y1.38%
GM growth 5Y6%
HHS Yearly Profit, Operating, Gross MarginsHHS Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 10 -10 -20 -30

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

5

2. HHS Health Analysis

2.1 Basic Checks

  • With a Return on Invested Capital (ROIC) below the Cost of Capital (WACC), HHS is destroying value.
  • Compared to 1 year ago, HHS has more shares outstanding
  • HHS has more shares outstanding than it did 5 years ago.
  • The debt/assets ratio for HHS has been reduced compared to a year ago.
HHS Yearly Shares OutstandingHHS Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2M 4M 6M
HHS Yearly Total Debt VS Total AssetsHHS Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 50M 100M 150M 200M

2.2 Solvency

  • An Altman-Z score of 14.61 indicates that HHS is not in any danger for bankruptcy at the moment.
  • HHS's Altman-Z score of 14.61 is amongst the best of the industry. HHS outperforms 95.60% of its industry peers.
  • HHS has a Debt/Equity ratio of 0.02. This is a healthy value indicating a solid balance between debt and equity.
  • The Debt to Equity ratio of HHS (0.02) is better than 79.12% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.02
Debt/FCF N/A
Altman-Z 14.61
ROIC/WACC0.28
WACC9.78%
HHS Yearly LT Debt VS Equity VS FCFHHS Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 20M -20M -40M

2.3 Liquidity

  • A Current Ratio of 1.54 indicates that HHS should not have too much problems paying its short term obligations.
  • With a decent Current ratio value of 1.54, HHS is doing good in the industry, outperforming 60.44% of the companies in the same industry.
  • HHS has a Quick Ratio of 1.54. This is a normal value and indicates that HHS is financially healthy and should not expect problems in meeting its short term obligations.
  • With a decent Quick ratio value of 1.54, HHS is doing good in the industry, outperforming 62.64% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 1.54
Quick Ratio 1.54
HHS Yearly Current Assets VS Current LiabilitesHHS Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 50M 100M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

0

3. HHS Growth Analysis

3.1 Past

  • HHS shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 97.36%, which is quite impressive.
  • The Revenue for HHS has decreased by -13.86% in the past year. This is quite bad
  • Measured over the past years, HHS shows a decrease in Revenue. The Revenue has been decreasing by -2.04% on average per year.
EPS 1Y (TTM)97.36%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%190%
Revenue 1Y (TTM)-13.86%
Revenue growth 3Y-8.21%
Revenue growth 5Y-2.04%
Sales Q2Q%-15.43%

3.2 Future

  • No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
HHS Yearly Revenue VS EstimatesHHS Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 100M 200M 300M 400M 500M
HHS Yearly EPS VS EstimatesHHS Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 -5 -10 -15

More info and screens

Find the best growth stocksShow best growing peers

1

4. HHS Valuation Analysis

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for HHS. In the last year negative earnings were reported.
Industry RankSector Rank
PE N/A
Fwd PE N/A
HHS Price Earnings VS Forward Price EarningsHHS Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 0 0 0 0 0 0 0 0 0 0

4.2 Price Multiples

  • Based on the Enterprise Value to EBITDA ratio, HHS is valued cheaply inside the industry as 97.80% of the companies are valued more expensively.
Industry RankSector Rank
P/FCF N/A
EV/EBITDA 2.32
HHS Per share dataHHS EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 5 10 15 20

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. HHS Dividend Analysis

5.1 Amount

  • HHS does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

HHS Fundamentals: All Metrics, Ratios and Statistics

HARTE-HANKS INC

NASDAQ:HHS (4/28/2026, 8:00:02 PM)

2.75

-0.02 (-0.72%)

Chartmill FA Rating
GICS IndustryGroupMedia & Entertainment
GICS IndustryMedia
Industry Strength21.74
Industry Growth21.74
Earnings (Last)03-12
Earnings (Next)05-07
Inst Owners31.25%
Inst Owner Change1.26%
Ins Owners38.17%
Ins Owner Change0%
Market Cap20.38M
Revenue(TTM)159.57M
Net Income(TTM)-811.00K
Analysts80
Price TargetN/A
Short Float %1.42%
Short Ratio5.53
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DP0%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 0.13
P/FCF N/A
P/OCF N/A
P/B 0.99
P/tB 1.03
EV/EBITDA 2.32
EPS(TTM)-0.11
EYN/A
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)-0.61
FCFYN/A
OCF(TTM)-0.23
OCFYN/A
SpS21.53
BVpS2.77
TBVpS2.68
PEG (NY)N/A
PEG (5Y)N/A
Graham Number0 (-100%)
Profitability
Industry RankSector Rank
ROA -0.88%
ROE -3.95%
ROCE 3.52%
ROIC 2.78%
ROICexc 3.05%
ROICexgc 3.09%
OM 1.36%
PM (TTM) N/A
GM 18.08%
FCFM N/A
ROA(3y)-10.64%
ROA(5y)1.85%
ROE(3y)-50.52%
ROE(5y)N/A
ROIC(3y)7.14%
ROIC(5y)10.79%
ROICexc(3y)8.81%
ROICexc(5y)13.03%
ROICexgc(3y)9.27%
ROICexgc(5y)13.3%
ROCE(3y)9.04%
ROCE(5y)13.65%
ROICexgc growth 3Y-44.49%
ROICexgc growth 5YN/A
ROICexc growth 3Y-44.71%
ROICexc growth 5YN/A
OM growth 3Y-42.96%
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y1.38%
GM growth 5Y6%
F-Score4
Asset Turnover1.74
Health
Industry RankSector Rank
Debt/Equity 0.02
Debt/FCF N/A
Debt/EBITDA 0.07
Cap/Depr 61.65%
Cap/Sales 1.73%
Interest Coverage 7.42
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.54
Quick Ratio 1.54
Altman-Z 14.61
F-Score4
WACC9.78%
ROIC/WACC0.28
Cap/Depr(3y)71.15%
Cap/Depr(5y)108.73%
Cap/Sales(3y)1.74%
Cap/Sales(5y)1.91%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)97.36%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%190%
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)-13.86%
Revenue growth 3Y-8.21%
Revenue growth 5Y-2.04%
Sales Q2Q%-15.43%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-71.73%
EBIT growth 3Y-47.64%
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y33.28%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y41.92%
OCF growth 3YN/A
OCF growth 5YN/A

HARTE-HANKS INC / HHS Fundamental Analysis FAQ

What is the ChartMill fundamental rating of HARTE-HANKS INC (HHS) stock?

ChartMill assigns a fundamental rating of 2 / 10 to HHS.


Can you provide the valuation status for HARTE-HANKS INC?

ChartMill assigns a valuation rating of 1 / 10 to HARTE-HANKS INC (HHS). This can be considered as Overvalued.


How profitable is HARTE-HANKS INC (HHS) stock?

HARTE-HANKS INC (HHS) has a profitability rating of 3 / 10.


What is the financial health of HARTE-HANKS INC (HHS) stock?

The financial health rating of HARTE-HANKS INC (HHS) is 5 / 10.